03 feb: Indstillinger fra Nomineringskomitéen i DONG Energy A/S
06 feb: Indre værdi af SmallCap Danmark A/S er opgjort til 85,0 kr. pr. ..
06-02-2017 06:39:19

Genmab Announces Updated 2016 Financial Guidance

Relateret indhold
19 jul - 
Onsdagens aktier: Mærsk sejler videre i sommerstille ma..
19 jul - 
Onsdagens aktier: Mærsk sejler videre i sommerstille og..
18 jul - 
Tirsdagens aktier: Gevinst til Mærsk kunne ikke hindre ..
Relateret debat
20 jul - 
Det er alt for tidligt at konkludere at Car-t bliver en..
20 jul - 
Tak for at nuancere debatten - det er altid sundt! &nbs..
20 jul - 
Cut him some slack .... The Note is a long time investo..

Company Announcement

Copenhagen, Denmark; February 6, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has updated its 2016 Financial Guidance. Based on preliminary reporting, Genmab is improving its 2016 financial guidance published on December 20, 2016. The table below summarizes our revised and previous guidance.

MDKK

Revised Guidance

Previous Guidance

Revenue

1,790 – 1,840

1,720 – 1,770

Operating expenses

(750) – (800)

(800) – (850)

Operating income

1,015 – 1,065

895 – 945

Cash position at end of year*

3,850 – 3,950

3,650 – 3,750

*Cash, cash equivalents, and marketable securities

The revenue range has increased primarily due to higher royalties on net sales of DARZALEX® by Janssen and achievement of additional DuoBody® milestones. Among other items, the operating expense range has decreased due to timing of clinical and pre-clinical expenses. The operating income range has increased due to the combination of higher revenue and lower expenses. Our cash position has increased mainly due to timing of operating expenses and other working capital adjustments.

As previously announced, the annual report for 2016 will be published on February 22, 2017.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.   

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 03

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Bredgade 34E

1260 Copenhagen K

Denmark

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 jul
GEN
Ja, det ligner simpelthen ingenting. Siden starten af 2012 er Genmab under ledelse af Jan W. kun ste..
23
18 jul
GEN
Genmabs kræftmiddel Darzalex virker til at have vundetindpas i både USA og Europa, og salget viser s..
3
20 jul
GEN
Hvorfor ansætter Genmab ikke bare TheNote. Han ved hvordan man kører sådan en biks. Nu syntes jeg ik..
2
20 jul
GEN
Der er vel ingen der forventer Genmab stiger i same hast som i 2013, 14 og 15 med ca. 100% per år. 2..
2
19 jul
GEN
Ligner noget, der er klar til at tage godt ben ned. Brudt linje og nu test. Høj volume sammen med la..
2
19 jul
GEN
Så ser det ikke ud til at vi kommer længere før Jan tager sig sammen til at indgå nye aftaler.   Mac..
2
19 jul
GEN
Heldigvis viser det sig at priser på Car-T teknologisk kræftbehandling ligger højt. Det har længe væ..
1
19 jul
GEN
Hvad er markedsværdien ved kurs 1450 incl warrants etc.
1
18 jul
GEN
Jo. 299 mio.$ :)
1

Nordea/CEO: Vigtigt med grundig analyse om hovedkvarter

20-07-2017 12:36:25
Det bliver til september, at Nordea afslører, om banken har tænkt sig at flytte sit hovedkvarter.Det fremgik af bankens regnskab torsdag morgen og blev uddybet senere over for Ritzau Finans.Udskydelsen skyldes dels nye initiativer, som banken skriver i regnskabet, og dels vigtigheden af at have yderligere tid til analyserne.- Vi tager beslutningen for de næste ti år. Vi har så småt fakta på plads,..

Aktier/middag: Storbankerne falder til bunds i C20 efter regnskaber

20-07-2017 11:33:47
Nordea og Danske Bank har ikke formået at stille investorerne tilfredse med deres respektive halvårsregnskaber torsdag, og derfor er de to aktier faldet til bunds og bidrager til at holde det danske eliteindeks tilbage.C20 Cap-indekset falder 0,1 pct. til 1176,18, mens der ellers er relativt godt humør på de europæiske børser. Risikoappetitten tager til efter fremgang på børserne i både Asien og U..

Danske/Jyske: Positive nedskrivninger lyser op i pænt regnskab - NY

20-07-2017 08:23:27
Det er især en sund udvikling i kundernes økonomi, der er et væsentligt element i et ganske fornuftigt regnskab fra Danske Bank.Der var dog på forhånd ventet pæne tal fra Danmarks største bank, og derfor bør aktien ikke rokke sig voldsomt i torsdagens handel på aktiemarkedet.Det vurderer aktieanalytiker Thomas Eskildsen fra Jyske Bank.- Det er et fint regnskab, og banken er inde i en ganske stabil..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora-aktien tager stort hop efter rygstød fra investeringsbank - NY
2
Aktier/middag: Storbankerne falder til bunds i C20 efter regnskaber
3
Torsdagens aktier: Pandora funklede mens Nordea og Danske skuffede
4
Nordea Q2: Skuffer tungt og udskyder beslutning om hovedkvarter
5
Danske Bank Q2: Sundere problemkunder sikrede pænt plus i kvartalet

Relaterede aktiekurser

Genmab A/S 1.432,00 -0,4% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. juli 2017 02:35:05
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170720.2 - EUROWEB6 - 2017-07-21 02:35:05 - 2017-07-21 02:35:05 - 1 - Website: OKAY